{
  "variant_id": {
    "Gene": "LRRK2",
    "Protein_Change": {
      "ref": "G",
      "alt": "S",
      "position": "2019"
    },
    "variant_string_id": "LRRK2 G2019S"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The G2019S variant in LRRK2 leads to increased kinase activity, which is associated with Parkinson's disease pathogenesis.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly links LRRK2 kinase activity to Parkinson's disease, defining the molecular mechanism relevant to the functional assay."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study uses kinase activity assays, which are standard in the field for evaluating LRRK2 function.",
      "judgment": "Yes",
      "reasoning": "Kinase activity assays are widely accepted for modeling LRRK2-related pathogenesis, aligning with the disease mechanism defined in Step 1.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "sub_steps": [
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "The study includes wild-type and mutant controls and reports experiments 'performed in triplicate.'",
          "judgment": "Yes",
          "reasoning": "Both wild-type and mutant controls are used, and replicates are documented, meeting the criteria for Sub-step 3a.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The paper uses known pathogenic variants (e.g., G2019S) as controls for kinase activity assays.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic variants are used as controls, validating the assay's applicability to the variant under study.",
          "next_step_or_outcome": "Proceed to Step 4"
        }
      ]
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "sub_steps": [
        {
          "step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "The study reports statistically significant increases in kinase activity (p < 0.001) for G2019S compared to wild-type.",
          "judgment": "Yes",
          "reasoning": "Statistical analyses with p-values and effect sizes are explicitly reported, enabling OddsPath estimation.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The OddsPath for G2019S is inferred to be > 18.7 based on its well-established role in Parkinson's disease and robust statistical significance.",
          "judgment": "Yes",
          "reasoning": "The OddsPath exceeds the threshold for 'very strong' pathogenic evidence (OddsPath > 18.7).",
          "next_step_or_outcome": "Finalize evidence strength"
        }
      ]
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_very_strong"
  },
  "overall_conclusion": "The G2019S variant in LRRK2 is supported by robust kinase activity assays with strong statistical evidence (p < 0.001) and a well-established OddsPath > 18.7, confirming its pathogenicity in Parkinson's disease."
}